• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disparity in market prices for hepatitis C virus direct-acting drugs.

作者信息

Andrieux-Meyer Isabelle, Cohn Jennifer, de Araújo Evaldo S Affonso, Hamid Saeed S

机构信息

Médecins Sans Frontières, Access Campaign, Geneva, 1211 Switzerland.

Médecins Sans Frontières, Access Campaign, Geneva, 1211 Switzerland.

出版信息

Lancet Glob Health. 2015 Nov;3(11):e676-7. doi: 10.1016/S2214-109X(15)00156-4.

DOI:10.1016/S2214-109X(15)00156-4
PMID:26475012
Abstract
摘要

相似文献

1
Disparity in market prices for hepatitis C virus direct-acting drugs.丙型肝炎病毒直接作用药物的市场价格差异。
Lancet Glob Health. 2015 Nov;3(11):e676-7. doi: 10.1016/S2214-109X(15)00156-4.
2
Hepatitis C: how has France limited the expenses related to new treatments?丙型肝炎：法国如何限制与新疗法相关的费用？
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):655-657. doi: 10.1080/14737167.2016.1247696. Epub 2016 Oct 27.
3
New hepatitis C therapies: the toolbox, strategies, and challenges.新型丙型肝炎治疗方法：工具包、策略和挑战。
Gastroenterology. 2014 May;146(5):1176-92. doi: 10.1053/j.gastro.2014.03.003. Epub 2014 Mar 12.
4
[Prescription of new HCV-drugs - what has to be considered judicially].[新型丙型肝炎病毒药物的处方——司法上必须考虑的事项]
Z Gastroenterol. 2015 Jan;53(1):43-5. doi: 10.1055/s-0034-1385774. Epub 2015 Jan 16.
5
Management of hepatitis B virus infection in the underprivileged world.贫困地区的乙型肝炎病毒感染管理
Liver Int. 2011 Jul;31(6):749-50. doi: 10.1111/j.1478-3231.2011.02477.x. Epub 2011 Feb 22.
6
NICE approval of new hepatitis drug could result in £700m bill for NHS.英国国家卫生与临床优化研究所（NICE）批准一种新型肝炎药物可能会让英国国民医疗服务体系（NHS）承担7亿英镑的费用。
BMJ. 2015 Oct 20;351:h5554. doi: 10.1136/bmj.h5554.
7
Overcoming injustice: A roadmap to improve access to hepatitis C virus therapy for our medicaid patients.克服不公：改善我们医疗补助患者获得丙型肝炎病毒治疗机会的路线图。
Hepatology. 2017 May;65(5):1735-1740. doi: 10.1002/hep.29095. Epub 2017 Mar 31.
8
Is hepatitis C virus eradication around the corner only 25 years after its discovery?丙型肝炎病毒的发现至今仅 25 年，是否即将被彻底清除？
Int J Antimicrob Agents. 2015 Feb;45(2):111-2. doi: 10.1016/j.ijantimicag.2014.09.001. Epub 2014 Sep 6.
9
[Financial burden of hepatitis C infection and its treatment].丙型肝炎感染及其治疗的经济负担
Orv Hetil. 2015 May 24;156(21):862-8. doi: 10.1556/650.2015.30182.
10
[Economic sustainability of therapies: considerations following the introduction of new drugs for hepatitis C virus].[治疗方法的经济可持续性：丙型肝炎病毒新药引入后的考量]
Recenti Prog Med. 2014 Jun;105(6):227-32. doi: 10.1701/1543.16849.

引用本文的文献

1
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination.丙型肝炎病毒：流行病学挑战与全球消除策略
Viruses. 2025 Jul 31;17(8):1069. doi: 10.3390/v17081069.
2
Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia.东欧和中亚丙型肝炎病毒病例发现与治疗的成本效益
Liver Int. 2025 Aug;45(8):e70199. doi: 10.1111/liv.70199.
3
Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children.《儿童丙型肝炎感染管理的最新临床指南》
Pathogens. 2024 Feb 16;13(2):180. doi: 10.3390/pathogens13020180.
4
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.马来西亚使用自愿和强制许可选择治疗丙型肝炎的两种方法的预算影响分析。
Front Public Health. 2023 Feb 22;11:1114560. doi: 10.3389/fpubh.2023.1114560. eCollection 2023.
5
Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches.亲环蛋白及其在丙型肝炎病毒和黄病毒感染中的作用：新型抗病毒方法的前景
Pathogens. 2021 Jul 17;10(7):902. doi: 10.3390/pathogens10070902.
6
Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.低、中收入国家的非流行型 HCV 基因型与现有直接作用抗病毒治疗方案耐药的风险。
J Hepatol. 2021 Aug;75(2):462-473. doi: 10.1016/j.jhep.2021.04.045. Epub 2021 May 8.
7
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.拉维达韦联合索磷布韦治疗无肝硬化或代偿期肝硬化的慢性丙型肝炎感染患者的疗效和安全性（STORM-C-1）：一项两阶段、开放标签、多中心、单臂、2/3 期临床试验的中期分析。
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16.
8
Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy.在直接抗病毒治疗时代预测丙型肝炎病毒治疗初治患者的治疗失败情况。
Front Pharmacol. 2020 Nov 13;11:551500. doi: 10.3389/fphar.2020.551500. eCollection 2020.
9
Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.实现药品全民健康覆盖的资金与服务组织：巴西情境下最佳投资与服务组织的经济评估
Front Pharmacol. 2020 Apr 14;11:370. doi: 10.3389/fphar.2020.00370. eCollection 2020.
10
The Elimination of Hepatitis C as a Public Health Threat.消除丙型肝炎作为公共卫生威胁。
Cold Spring Harb Perspect Med. 2020 Apr 1;10(4):a036939. doi: 10.1101/cshperspect.a036939.